Screening

Precision Insight into Editing Efficiency and Safety, Early

INDUCE-seq® is a powerful platform technology designed to support the development of gene therapies and gene-edited cell therapies by providing comprehensive, unbiased mapping of double-strand DNA breaks. Its highly sensitive, PCR-free approach allows for accurate detection of both on-target and off-target editing events at single-nucleotide resolution that is critical for evaluating drug candidates that rely on gene editing.

In the early discovery and screening phase of drug development, INDUCE-seq can be offered in a higher throughput option for:

• Quantify on-target editing efficiency across different cell types, including primary human cells, T cells, and iPSCs, enabling favorable selection of candidates.
• Guide development: Look at on and off target gene editing activity to compare guide RNAs.
• Detect and eliminate drug candidates with off-target effects early in development, improving the safety profile of lead candidates and reducing costly downstream failures.
• Characterize and screen novel gene editing nucleases using single-nucleotide resolution readout of break end structure. 
• Compare multiple editing approaches side-by-side to identify the most precise and effective gene-editing strategies for a given therapeutic target and identify non-productive guides early.

This dual capability makes INDUCE-seq an essential tool for derisking gene-edited therapeutics, accelerating preclinical development, and building confidence in the safety efficiency of drug candidates headed for the clinic.